Hospitals in Taiwan use digital technology to implement medical care

2023-12-01 / GlobalBio & Investment
【Editor'sChoice|Taiwan’sMedicalDevice】Shortenunhealthylifeyears!HospitalsinTaiwanusedigitaltechnologytoimplementmedicalcare TheaveragelifeexpectancyofTaiwanesepeoplehasexceeded80years,butthe...

Rebuilding Psychological Safety After Drug Allergy: A 4-Step Approach

2023-12-01 / GlobalBio & Investment
RebuildingPsychologicalSafetyAfterDrugAllergy:A4-StepApproachAdrugallergyoccurswhentheimmunesystemreactstoanonprescription,prescription,orherbalmedicine.Patientssufferingfromdrugallergiesexperiencevar...

The Winners of 2023 Best Bio CEO Award held by Globalbio have been revealed!

2023-12-01 / GlobalBio & Investment
TheWinnersof2023BestBioCEOAwardheldbyGlobalbiohavebeenrevealed!Thisyearwehave CytoArm|Armed-Tcelltherapy, LeadgeneBiomedical,Inc.,and SunWayBiotechCo.,LTD. winningtheawards.Thefirstwinner,CytoArm,feat...

AI Revolutionizing Biomedicine: Recent Advances and Healthcare Applications

2023-12-01 / GlobalBio & Investment
AIRevolutionizingBiomedicine:RecentAdvancesandHealthcareApplicationsAIanditsgenerativecapabilitieshavegainedsignificantattention,particularlyinthefieldofbiomedicine,sinceChatGPT'srisetoprominencei...

Sarepta天價基因療法再遭抨擊!ICER醫療長投書《JAMA》質疑FDA加速批准

2024-05-06 / 記者 吳培安
基因療法批准再起爭議!日前(1日),美國非營利組織臨床和經濟審查研究所(ICER)醫療長DavidRind於指標性國際期刊《美國醫學會雜誌》(JAMA)發表文章,質疑美國食品藥物管理局(FDA)在去(2023)年6月同意以加速批准途徑,讓由SareptaTherapeutics開發、在兩項臨床研究中皆未能達成主要療效指標的基因療法Elevidys,作為裘馨氏肌肉失養症(DMD)療法上市的決策。 R...

76-year-old CSD Successfully Transitions to B2C with Innovative 'Health in Style' Products.

2023-12-01 / GlobalBio & Investment
【Editor'sChoice|Taiwan'sMedicalDevice】76-year-old #CSD SuccessfullyTransitionstoB2CwithInnovative'HealthinStyle'Products. CSD,aleadingbrandinTaiwanforhealthprotectionsupplieswitha76-ye...

Next Step: Targeting Neurological Disorders and Cancer Treatment?!

2023-12-01 / GlobalBio & Investment
【Editor'sChoice|Storiesbehind #BIO2023】ModernaCo-founderandAlnylamSeniorVicePresident:WitnessingthePotentialofNucleicAcidTherapyinthePandemic!NextStep:TargetingNeurologicalDisordersandCancerTreatm...

Dr. Frank Kung of Vivo Capital Shares US Biotech Trends

2023-12-01 / GlobalBio & Investment
Dr.FrankKungofVivoCapitalSharesUSBiotechTrends:WeaknessContinuesAfter2021Peak,BigPharmaSeeksM&A,IntenseOncology&RareDiseaseCompetitionDr.FrankKung,co-founderandexecutivedirectorofVivoCapitalre...

Genomics Raises 4.88 Million in Seasoned Equity Offering

2023-12-01 / GlobalBio & Investment
【Editor'sChoice|GenomeSequencing】UpgradedManufacturingProcessesforDomesticNucleicAcidandPeptide!GenomicsRaises4.88MillioninSeasonedEquityOffering GenomicsBioSci&Tech(4195.TWO)recentlyannounced...

美最新乳癌預防指引:40歲以上女性應每兩年一次乳房X光檢查

2024-05-06 / 記者 巫芝岳
近日(4月30日),美國預防服務工作組(USPSTF),在醫學期刊《JAMA》中正式發布其最新的乳癌預防指引,建議40~74歲的女性,應每兩年接受一次乳房X光攝影檢查。而根據台灣國健署目前的資訊,政府補助國內45~70歲女性每兩年一次乳房X光攝影檢查;40~45歲具有乳癌家族史的女性則為每兩年一次。根據USPSTF最新建議,由於美國40多歲女性的乳癌罹患率,正以每年增加2%的速率成長中,因此提出本...

一次血檢測1,000種病原體!Karius C輪募1億美元

2024-05-06 / 記者 彭梓涵
近(3)日,傳染病診斷開發商Karius宣布,完成C輪1億美元募資,該筆資金將加速Karius僅需血液樣本就能檢測1,000種微生物病原體的檢測產品,其臨床研究和商業開發。Karius加上前面幾輪募資,已募得總資金超過3億美元。 Karius開發的產品,是透過總體基因體定序(metagenomics)、人工智慧技術,從血液樣本分析1,000種游離病原體DNA(mcfDNA),以判讀感染狀況與風險。...

浩宇攜超音波顯影劑大廠Bracco 開發無創精準治療;安進2024Q1營收增22% 創新減肥藥將進三期

2024-05-06 / 環球生技
《臺灣》浩宇攜超音波顯影劑大廠Bracco開發無創精準治療 昨(6)日,浩宇生醫(6872)宣布已和超音波顯影劑領導品牌Bracco,在4月26日簽署了一項合作協議,Bracco將提供其微氣泡顯影產品,搭配浩宇的聚焦式超音波系統NaviFUS,作為開啟血腦屏障的技術平台。這項合作將由浩宇進行各項腦部癌症或神經疾病治療的臨床試驗與查驗登記,預計在取得上市許可後,由Bracco負責供應此微氣泡貼牌產品...